293 related articles for article (PubMed ID: 26696010)
1. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Martinelli I; Lensing AW; Middeldorp S; Levi M; Beyer-Westendorf J; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Trajanovic M; Gebel M; Lam P; Wells PS; Prins MH
Blood; 2016 Mar; 127(11):1417-25. PubMed ID: 26696010
[TBL] [Abstract][Full Text] [Related]
2. Less menorrhagia for women with VTE.
Schulman S
Blood; 2016 Mar; 127(11):1378-9. PubMed ID: 26989185
[TBL] [Abstract][Full Text] [Related]
3. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
Bryk AH; Piróg M; Plens K; Undas A
Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826
[TBL] [Abstract][Full Text] [Related]
4. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Robertson L; Yeoh SE; Ramli A
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
[TBL] [Abstract][Full Text] [Related]
6. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
8. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
10. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Huisman MV; Ferreira M; Feuring M; Fraessdorf M; Klok FA
J Thromb Haemost; 2018 Sep; 16(9):1775-1778. PubMed ID: 29974611
[TBL] [Abstract][Full Text] [Related]
11. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
Bistervels IM; Bavalia R; Gebel M; Lensing AWA; Middeldorp S; Prins MH; Coppens M
J Thromb Haemost; 2022 Jun; 20(6):1376-1384. PubMed ID: 35253983
[TBL] [Abstract][Full Text] [Related]
12. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
[TBL] [Abstract][Full Text] [Related]
13. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists.
De Crem N; Peerlinck K; Vanassche T; Vanheule K; Debaveye B; Middeldorp S; Verhamme P; Peetermans M
Thromb Res; 2015 Oct; 136(4):749-53. PubMed ID: 26272306
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
15. Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report.
Giustozzi M; Vedovati MC; Agnelli G
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):391-394. PubMed ID: 29346128
[TBL] [Abstract][Full Text] [Related]
16. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
19. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Davidson BL; Verheijen S; Lensing AW; Gebel M; Brighton TA; Lyons RM; Rehm J; Prins MH
JAMA Intern Med; 2014 Jun; 174(6):947-53. PubMed ID: 24733305
[TBL] [Abstract][Full Text] [Related]
20. Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA.
Weaver J; Shoaibi A; Truong HQ; Larbi L; Wu S; Wildgoose P; Rao G; Freedman A; Wang L; Yuan Z; Barnathan E
Drug Saf; 2021 Apr; 44(4):479-497. PubMed ID: 33651368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
